Relief Therapeutics

Relief Therapeutics will merge with NeuroX, the successor to MindMaze, in a deal valuing Relief at CHF 100M and NeuroX at CHF 1B. Relief shareholders will own approximately 9% of the combined entity, focused on AI-based digital neurotherapeutics. NeuroX, which acquired MindMaze’s assets, brings a clinically validated platform with over $350M invested. The transaction is expected to close in Q4 2025, pending approvals and customary conditions. The merger aims to create a publicly listed, AI-driven health tech enterprise.